
Dialysis provider DaVita Inc. (NYSE: DVA) will be reporting earnings this Thursday after the bell. Here’s what investors should know.
DaVita beat analysts’ revenue expectations last quarter, reporting revenues of $3.55 billion, up 5.2% year on year. It was a mixed quarter for the company, with a beat of analysts’ EPS estimates but a miss of analysts’ full-year EPS guidance estimates.
Is DaVita a buy or sell going into earnings? Read our full analysis here, it’s free for active Edge members.
This quarter, the market is expecting DaVita’s revenue to grow 2.8% year on year, slowing from the 4.8% increase it recorded in the same quarter last year.

Analysts covering the company have generally reconfirmed their estimates over the last 30 days, suggesting they anticipate the business will stay the course heading into earnings. DaVita rarely misses Wall Street’s revenue estimates.
Looking at DaVita’s peers in the healthcare providers & services segment, some have already reported their Q3 results, giving us a hint as to what we can expect. Elevance Health posted flat year-on-year revenue, beating analysts’ expectations by 3.1%, and UnitedHealth reported flat revenue, topping estimates by 1.2%. Elevance Health traded up 1.2% following the results while UnitedHealth was also up 4.5%.
Read our full analysis of Elevance Health’s results here and UnitedHealth’s results here.
There has been positive sentiment among investors in the healthcare providers & services segment, with share prices up 3.6% on average over the last month. DaVita is up 1.4% during the same time and is heading into earnings with an average analyst price target of $219.86 (compared to the current share price of $180.55).
ONE MORE THING: The $21 AI Application Stock Wall Street Forgot. While Wall Street obsesses over who’s building AI, one company is already using it to print money. And nobody’s paying attention.
AI chip stocks trade at ridiculous valuations. This company processes a trillion consumer signals monthly using AI and trades at a third of the price. The gap won’t last. The institutions will figure it out. You need to see this first. Read the FREE Report Before They Notice.
